BioHarvest Sciences (BHST) Q3 Investor Summit Group Virtual Conference 2026 earnings summary

Team and leadership

• Executive team averages 10 years of experience, spanning biology, finance, manufacturing, sales, and consumer goods.

• Co-founder has been with the company since inception, contributing to stability and expertise.

Platform technology and business model

• Developed a platform for industrial-scale plant cell culture, producing plant-based molecules without growing whole plants.

• Focuses on nutraceuticals, cosmeceuticals, pharma, and nutrition sectors as a CDMO.

• Four major partnerships established across these sectors.

• Botanical Synthesis platform validated by commercializing VINIA, with $100 million in cumulative sales.

• Holds 15 patents and positions itself as a strategic partner for development and manufacturing.

Market opportunity and technology differentiation

• Addresses demand for proprietary, efficacious, and sustainable natural molecules in fast-growing markets.

• Overcomes supply chain risks and inconsistencies of traditional agriculture with controlled industrial biology.

• Uses programmable plant biology to create cell banks, enabling large-scale, consistent production.

• No genetic modification involved; unique growth conditions elicit desired molecules.